Literature DB >> 4139232

Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB-NZW F1 mice.

S Sugai, D W Palmer, N Talal, I P Witz.   

Abstract

A spontaneous lymphoma (141) producing monoclonal IgM is established in NZB/NZW F(1) (B/W) mice who spontaneously develop an autoimmune disease. Idiotypic determinants of 141 IgM are present on the lymphoma cell surface as shown by indirect immunofluorescence and specific cytotoxicity with rabbit anti-idiotypic antiserum. Fluorescence and cytotoxicity are inhibited by 141 IgM but not by 104E IgM, a monoclonal IgM produced by a BALB/c plasmacytoma. Immunization of B/W mice with 141 IgM before transplantation of lymphoma 141 confers protective immunity. No such protection occurs after immunization with 104E IgM or other unrelated proteins. Protected mice contain spleen cells cytotoxic for 141 lymphoma cells. This cytotoxicity is blocked by incubation of spleen cells with 141 IgM but not with 104E IgM. Moreover, splenic lymphocytes from protected mice are stimulated to synthesize DNA by 141 IgM but not by 104E IgM. These results suggest that specific cellular immune responses to idiotypic determinants may participate in the observed protection against challenge with the corresponding B-cell tumor.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4139232      PMCID: PMC2139761          DOI: 10.1084/jem.140.6.1547

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  26 in total

Review 1.  Immunoglobulin-producing tumors and myeloma proteins of mice.

Authors:  M Potter
Journal:  Physiol Rev       Date:  1972-07       Impact factor: 37.312

Review 2.  Cooperating and controlling functions of thymus-derived lymphocytes in relation to autoimmunity.

Authors:  A C Allison; A M Denman; R D Barnes
Journal:  Lancet       Date:  1971-07-17       Impact factor: 79.321

3.  Precipitation of radioactively labeled samples: a semi-automatic multiple-sample processor.

Authors:  R J Hartzman; M L Bach; F H Bach; G B Thurman; K W Sell
Journal:  Cell Immunol       Date:  1972-06       Impact factor: 4.868

4.  Immunologic and viral factors in the pathogenesis of systemic lupus erythematosus.

Authors:  N Talal
Journal:  Arthritis Rheum       Date:  1970 Nov-Dec

5.  Quantitative in vitro assay of cytotoxic cellular immunity.

Authors:  T G Canty; J R Wunderlich
Journal:  J Natl Cancer Inst       Date:  1970-10       Impact factor: 13.506

6.  The natural history of the NZB/NZW F1 hybrid mouse: a laboratory model of systemic lupus erythematosus.

Authors:  F M Burnet; M C Holmes
Journal:  Australas Ann Med       Date:  1965-08

7.  Myeloma proteins as tumor-specific transplantation antigens.

Authors:  R G Lynch; R J Graff; S Sirisinha; E S Simms; H N Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1972-06       Impact factor: 11.205

8.  Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins.

Authors:  S Sirisinha; H N Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1971-12       Impact factor: 11.205

9.  Natural thymocytotoxic autoantibody and reactive antigen in New Zealand black and other mice.

Authors:  T Shirai; R C Mellors
Journal:  Proc Natl Acad Sci U S A       Date:  1971-07       Impact factor: 11.205

10.  Pathogenesis of the glomerulonephritis of NZB/W mice.

Authors:  P H Lambert; F J Dixon
Journal:  J Exp Med       Date:  1968-03-01       Impact factor: 14.307

View more
  12 in total

Review 1.  Vaccination strategies for lymphomas.

Authors:  Mohammed M Dar; Larry W Kwak
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

2.  Systemic lupus erythematosus and malignancies risk.

Authors:  Song Mao; Hua Shen; Jianhua Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-29       Impact factor: 4.553

Review 3.  Systemic lupus erythematosus and increased risk to develop B cell malignancies: role of the p200-family proteins.

Authors:  Sudhakar Veeranki; Divaker Choubey
Journal:  Immunol Lett       Date:  2010-06-26       Impact factor: 3.685

4.  Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response.

Authors:  L W Kwak; H A Young; R W Pennington; S D Weeks
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

5.  Immunoglobulin synthesis by an SV-40-induced hamster lymphoma.

Authors:  J E Coe
Journal:  Immunology       Date:  1976-09       Impact factor: 7.397

6.  Stimulated autoantibody response and increased longevity in NZB/NZW mice treated with cyclophosphamide and tilorone.

Authors:  S E Walker; M R Anver
Journal:  Clin Exp Immunol       Date:  1978-09       Impact factor: 4.330

7.  Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors.

Authors:  G F Lauritzsen; S Weiss; Z Dembic; B Bogen
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

8.  Induction of tumor immunity by intact irradiated leukemic B cells (BCL1) bearing a tumor-associated cell-surface idiotype and the costimulatory B7 molecule.

Authors:  S Morecki; S Levi; Y Puyesky; S Slavin
Journal:  Cancer Immunol Immunother       Date:  1995-10       Impact factor: 6.968

Review 9.  Therapeutic vaccine for lymphoma.

Authors:  Seung-Tae Lee; Sattva S Neelapu; Larry W Kwak
Journal:  Yonsei Med J       Date:  2007-02-28       Impact factor: 2.759

10.  Suppression of in vivo tumor formation induced by simian virus 40-transformed cells in mice receiving antiidiotypic antibodies.

Authors:  R C Kennedy; G R Dreesman; J S Butel; R E Lanford
Journal:  J Exp Med       Date:  1985-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.